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ABSTRACT: Halloysite clay nanotubes (HNTs) have been proposed as highly
biocompatible for several biomedical applications. Various polymers have been
used to functionalize HNTs, but scarce information exists about polystyrene for
this purpose. This work evaluated polystyrene-functionalized HNTs (FHNTs)
by comparing its effects with non-FHNTs and innocuous talc powder on in vitro
and in vivo models. Monocyte-derived human or murine macrophages and the
RAW 264.7 cell line were treated with 0.01, 0.1, 1, and 100 μg mL−1 FHNTs,
HNTs, or talc to evaluate the cytotoxic and cytokine response. Our results show
that nanoclays did not cause cytotoxic damage to macrophages. Only the 100 μg
mL−1 concentration induced slight proinflammatory cytokine production at
short exposure, followed by an anti-inflammatory response that increases over
time. CD1 mice treated with a single dose of 1, 2.5, or 5 mg Kg−1 of FHNTs or
HNTs by oral and inhalation routes caused aluminum accumulation in the
kidneys and lungs, without bodily signs of distress or histopathological changes
in any treated mice, evaluated at 48 h and 30 days post-treatment. Nanoclay administration simultaneously by four different
parenteral routes (20 mg Kg−1) or the combination of administration routes (parenteral + oral or parenteral + inhalation; 25 mg
Kg−1) showed accumulation on the injection site and slight surrounding inflammation 30 days post-treatment. CD1 mice chronically
exposed to HNTs or FHNTs in the bedding material (ca 1 mg) throughout the parental generation and two successive inbred
generations for 8 months did not cause any inflammatory process or damage to the abdominal organs and the reproductive system of
the mice of any of the generations, did not affect the number of newborn mice and their survival, and did not induce congenital
malformations in the offspring. FHNTs showed a slightly less effect than HNTs in all experiments, suggesting that functionalization
makes them less cytotoxic. Doses of up to 25 mg Kg−1 by different administration routes and permanent exposure to 1 mg of HNTs
or FHNTs for 8 months seem safe for CD1 mice. Our in vivo and in vitro results indicate that nanoclays are highly biocompatible,
supporting their possible safe use for future biomedical and general-purpose applications.
1. INTRODUCTION
Nanoclay property and application study is a research area that
is rapidly growing due to their potential for biomedical
applications.1,2 Mainly, halloysite [Al2Si2O5(OH)4·nH2O] has
been extensively studied due to its structural features: porosity,
tube lumen size, and particular inner/outer surface chemistry.
The inner surface corresponds to aluminum oxides, while silica
makes up the external sheets, which gives it advantages on the
loading and controlled release of drugs and genes compared
with other clays.3 Halloysite nanotubes (HNTs) are viable and
inexpensive nanoscale containers4−8 enhancing the loading and
controlled release of drugs and genes,9,10 organosilanes,11 or
nitric oxide12 and also functioning as biomimetic nano-
reactors.11,13 The HNT functionalization with polymeric
materials such as polyethyleneimine, polycaprolactone, poly-
(N-isopropyl acrylamide), chitosan, gelatin elastomers, endo-
dontic sealers, or adhesive resins14 gives them other functions
including antimicrobial activity,15−19 antitumor activity,20,21
brain disorder treatment,22 wound-healing materials,2 bone
repairing,9 tissue regeneration,23,24 and as a filler for general-
purpose materials.6,20,25,26
HNT toxicity has been evaluated on different in vitro
models, including neoplastic cell lines,27 fibroblasts,28 human
Received: August 12, 2021
Accepted: October 14, 2021
Articlehttp://pubs.acs.org/journal/acsodf

























































































intestinal Caco-2 cells,29 human peripheral blood lympho-
cytes,30 and red blood cells.31 In all cases, HNTs are shown to
be nontoxic or scarcely toxic under the tested conditions. In
contrast, oral administration of HNTs for 30 days induces a
fibrotic response in the lung and oxidative damage in the liver
of mice.32,33 An increase in the HNT surface enhanced
pulmonary tissue inflammatory cytotoxicity in C57BL/6
JBomTac mice.34 Functionalization of HNTs with trimethoxy-
(propyl)silane and triethoxy(octyl)silane causes apoptosis in
C6 rat glioblastoma cells.35 Meanwhile, HNT attachment to
Fe3O4 nanoparticles induces higher cytotoxicity than Fe3O4
nanoparticles on A-549 cell lines.36 These examples show the
potential toxicity of nanoclays in vivo and the substantial role of
the surface functionalization on the toxic effect produced.
To our knowledge, polystyrene has been scarcely studied
compared to other polymers to functionalize HNTs, although
polystyrene is one of the most widely used polymers in food
containers, food-contact applications, laboratory products,
medical devices, cosmetics, pharmaceutics, and cleaning agents
due to its inertness and high biocompatibility.37 Therefore, this
study assessed the in vitro and in vivo biocompatibility of
nonfunctionalized HNTs and polystyrene-functionalized
HNTs (FHNTs). The latter was described previously and
entirely characterized by Flores-Santos.25 For in vitro tests, we
evaluated the effect of nanoclays on macrophages, considering
that they are the main phagocytic cells in the body and leading
players in the immunological response. HNTs or FHNTs were
administered to macrophages derived from human and mouse
monocytes and macrophages from the RAW 264.7 cell line to
evaluate their effect on the viability and cytokine release.
Furthermore, toxicity after acute, semiacute, and chronic
exposure of CD1 mice throughout different administration
routes was evaluated, including the second-generation off-
spring.
2. RESULTS AND DISCUSSION
2.1. Characterization of HNTs and FHNTs. Synthesis
and characterization of FHNTs and HNTs used here are
reported in the US Patent Application US 2008200601A1.25
Briefly, HNTs were obtained by grinding and sieving natural
halloysite; meanwhile, FHNTs were obtained by a surface
treatment of HNTs with copolymer styrene as a functionaliz-
ing agent. HNT and FHNT physicochemical properties were
quite similar (Table 1). Both samples show a hollow tubular
structure, as determined by transmission electron microscopy
(TEM) with average diameters of 76 and 82 nm for HNTs and
FHNTs, respectively (Figure 1).
2.2. Cytotoxicity Assays. The nanoclay-induced effects on
human and murine macrophage viability and cell death
pathways (apoptosis and necrosis) at concentrations of 0.01,
0.1, 1, 10, and 100 μg mL−1 were determined by flow
cytometry using Annexin V/propidium iodide. Talc powder
was used as a negative control for comparative purposes.38
Macrophage cultures treated with FHNTs, HNTs, and talc
showed minimal viability decrease (less than 5%) independent
of exposure time with concentrations within the range of 0.01−
10 μg mL−1. When evaluating at the concentration of 100 μg
mL−1, a time-dependent decrease in viability was observed, but
it did not exceed 10% at the maximum exposure time of 60 h
for RAW 264.7 and human peripheral blood monocytes
(HMDM). The effect was slightly greater in mice bone marrow
monocytes (MMDM) but did not exceed 15% at 60 h (Figure
2, upper panel). No differences were found in the viability of
macrophages exposed to halloysites with respect to talc.
Overall, the statistical analysis showed no significant differ-
ences between groups, independently of the macrophage
source, exposure time, or studied material.
When the type of cell death induced by halloysite nanoclays
was analyzed, it was found that murine macrophages exposed
to 100 μg mL−1 HNTs or FHNTs, either the RAW 264.7 cell
line or MMDM, exhibited higher levels of apoptosis (from 2-
5%) than human macrophages HMDM (0.5−1.5%) (Figure 2,
middle panel). Conversely, 2−12% of necrosis was found on
human macrophages exposed to 100 μg mL−1 HNTs or
FHNTs, whereas just 1 to 2% was observed on murine
macrophages (Figure 2, lower panel). The mechanisms of the
apoptosis triggered in these macrophages by the nanoclays
remain unknown and warrant further study. Still, it could
involve surface scavenger receptors and the activation of
mitochondrial caspase 9, as described for multiwall nano-
tubes.39
The functionalization of HNTs with polystyrene (FHNTs)
did not modify the cytotoxic effect on macrophages compared
with that of HNTs. Considering the high amount of material
employed to produce a small decrease in viability, these results
suggest that none of the materials assessed herein were
significantly toxic to macrophages. Our results are in
agreement with those on HNT toxicity in macrophages of
the RAW 264.7 cell line by Wu and co-workers.31 They found
that 100 μg mL−1 HNTs were incorporated around the cell
nucleus without producing cytotoxic damage to macrophages.
Besides, human peripheral blood lymphocytes incubated with a
halloysite suspension did not show a significant deleterious
effect,40 and the effect in human pancreatic cells (Panc-1) was
described as insignificant.41 Likewise, when compared with
other nanoclays, such as clinoptilolite or sepiolite, HNTs
showed lower toxicity over macrophage cell cultures, causing
only half of the cytotoxic effect observed with those other
nanoclays.42 The high cyto- and biocompatibility of HNTs
have also been confirmed in freshwater unicellular organisms
such as the protozoa Paramecium caudatum (a maximum safe
Table 1. Physicochemical Properties of HNTs and FHNTs
properties units HNTs FHNTs
humidity % 1.51 1.15
bulk density g mL−1 0.12 0.12
ashes % 85.39 83.34
conductivity μS 231 192
length/diameter dimensionless 9 9
average diameter nm 76 82
Figure 1. TEM images of the halloysite nanotube powder used in this
work. Both HNTs and FHNTs show a typical hollow tubular shape
with diameters down to 100 nm on average.
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dose of 1 mg mL−l) and multicellular organisms such as the
nematode Caenorhabditis elegans (1 mg mL−l) and the larvae of
zebra fish (up to 10 mg mL−l).43−45 Our results show that
HNTs and FHNTs with concentrations up to 100 μg mL−1 are
safe for macrophages in vitro, independent of their source. This
concentration of HNTs agrees with those previously reported
as the maximum concentration at which the nanoclays do not
kill Hela and MCF-7 cell lines (75 μg mL−1).27 In summary,
our results and several others in the literature15,43−47 agree
regarding the low cytotoxicity of HNTs and FHNTs in in vitro
studies.
2.3. Cytokine Production. Given that FHNTs could have
many biomedical applications, we considered it essential to
evaluate the ability of these nanoclays to activate proin-
flammatory responses in macrophages. Cytokines IFN-γ, IL-
1α, IL-6, IL-8, IL-10, and IL-17 produced by HMDM and
MMDM cultures exposed to 100 μg mL−1 HNTs, FHNTs, or
talc were quantified. The RAW 264.7 cell line was excluded in
this experimental section because of our interest in evaluating
the inflammatory effects on primary cultures. Exposure of the
HMDM and MMDM cultures to FHNTs did not induce the
release of inflammatory cytokines IL-1α and IL-6 at any time
assessed, remaining at baseline levels. Moreover, no expression
of the proinflammatory cytokine INF-γ was detected. Only a
slight increase in IL-8 levels over time was observed in
MMDM cultures exposed to FHNTs compared to that with
talc but not in HMDM cultures. With this exception, the
production of inflammatory cytokines promoted by FHNTs
was lower than that produced by HNTs and talc, significantly
much lower compared to the latter. Furthermore, the exposure
of macrophages to either nanoclay induced the release of the
regulatory cytokine IL-10, whose levels increased over time, as
well as an increase in IL-7 levels but only at late times (Figure
3).
It is known that Th1 cytokine secretion is associated with a
proinflammatory response, whereas Th2 cytokines counteract
this Th1 response, reducing inflammation; meanwhile, IL-10
has a regulatory effect.48 Herein, we found that macrophage
cultures treated with FHNTs or HNTs do not exhibit a specific
cytokine pattern. The low production of the proinflammatory
cytokines IL-1α and IL-6, together with the absence of INFγ, is
related to a low inflammatory potential. In contrast, it is well-
known that the secretion of IL-8 favors the recruitment of
immune cells, mainly neutrophils, together with a Th1-
associated immune response.49 In this sense, most biocompat-
ible materials have been shown to induce the secretion of
proinflammatory cytokines such as TNF-α, although its
expression tends to decrease over time.49 On the other hand,
the induction of the regulatory cytokine IL-10 over time
suggests a possible role in resolving any early inflammation.
Thus, IL-10 secretion is related to the regulation of
inflammatory processes and biocompatibility, contributing to
Figure 2. Macrophage viability and type of cell death induced by HNTs, FHNTs, and talc at 100 μg mL−1. The RAW 264.7 cell line and
macrophages from mice bone marrow monocytes and HMDMs were stained with Annexin V and propidium iodide to evaluate the viability,
apoptosis, and necrosis. Evaluations at 12, 24, 36, 48, and 60 h are shown.
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the inhibition or resolution of the inflammation associated with
nanocomposites.48 On the other hand, the release of IL-17 at
later times could suggest that halloysite nanoclays, but mainly
talc, have the potential to induce allergic responses as this
cytokine has been related to anaphylaxis.50 Overall, our results
show that FHNTs and HNTs are poor inducers of
proinflammatory cytokines in human and mouse macrophage
cultures, which, in association with the induction of IL-10,
suggests that halloysite nanoclays are well-tolerated by the
macrophages, even better than talc.
2.4. Effect of Acute and Semiacute Exposure in Mice.
To support and complement the results obtained in vitro, we
evaluated the toxicity of halloysite nanoclays in experimental
mice following acute and chronic exposure protocols. Here, we
analyzed acute (24 h) and semiacute (30 days) effects of
nanoclays on inbred CD1 mice, the preferred strain of mice for
toxicity studies due to its variability between individuals.51,52
HNT or FHNT administration (1, 2.5, or 5 mg Kg−1) in CD1
mice by any of the assessed routes and their combinations
(oral, respiratory, cutaneous, subcutaneous, intramuscular, and
intraperitoneal routes) did not induce any notable physio-
logical change in the animals during the time the experiment
lasted (30 days). Thus, the treated mice did not show apparent
bodily signs of disease, such as bristly hair, diarrhea, vomiting,
or infirmity (data not shown). Furthermore, the body
temperature (36.5 ± 0.7 °C) and the weight of mice
(approximately 35 g for females and 45 g for males) were
within normal ranges throughout the 30 days.
Since renal and hepatobiliary systems are the most
important routes for the elimination of foreign substances
and particles, nanoclays could accumulate in these organs,
causing tissue damage.53 We determined the renal and hepatic
functionality of mice treated with halloysite nanoclays by
quantifying the serum hallmark parameters alanine and
aspartate aminotransferases, creatinine, urea, bilirubin, and
total proteins after 48 h and 30 days of exposure (Table 2). All
the parameters in the sera of the mice treated with the
nanoclays, regardless of whether they were functionalized or
not, were within the range of reference values and did not
show significant differences with respect to the values in
Figure 3. Cytokine expression in macrophages exposed to halloysite nanoclays. Cytokines IFN-γ, IL-1α, IL-6, IL-8, IL-10, and IL-17 were
quantified by flow cytometry in (A) HMDM cultures and (B) MMDM cultures after exposure to 100 μg mL−1 FHNTs, HNTs, or talc for 24, 36,
and 48 h.
Table 2. Serological Values of Liver and Kidney Function Parameters in Mice Treated with Halloysite Nanoclaysa
24 h 48 h
units reference control FHNTs HNTs control FHNTs HNTs
urea mmol mL−1 8.87 ± 1.61 7.61 ± 1.13 5.1 ± 0.3 9.2 ± 0.7 8.5 ± 0.4 7.56 ± 0.4 8.21 ± 0.8
AST U L−1 82.80 ± 39.85 79 ± 12.6 78 ± 4.6 70 ± 11.5 78 ± 9.6 78 ± 5.6 87 ± 7.3
ALT U L−1 45.08 ± 16.11 35 ± 7.5 39 ± 2.3 30 ± 0.7 38 ± 6.8 40 ± 3.5 39 ± 3.7
creatinine μM mL−1 10.73 ± 2.19 8.8 ± 1.2 9.1 ± 0.4 8.7 ± 0.1 8.8 ± 0.2 8.7 ± 0.2 9.1 ± 0.3
total protein g L−1 52.30 ± 11.13 54 ± 6.4 54 ± 3.6 45 ± 2.3 56 ± 5.2 54 ± 5.3 53 ± 4.7
total bilirubin μM mL−1 3.2 ± 1.2 2.37 ± 0.6 2.11 ± 0.3 2.23 ± 0.1 2.26 ± 0.1 2.3 ± 0.2 2.6 ± 0.2
aThe mice were exposed to 5 mg Kg−1 HNTs or FHNTs, and the values of urea, alanine aminotransferase (ALT), aspartate aminotransferase
(AST), creatinine, total protein, and total bilirubin were determined at 48 h and 30 days post-treatment. All parameters were within the range
reported as standard by the Charles River Laboratories.
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untreated control mice (Table 2). A slight decrease in urea was
observed in the sera of mice treated with FHNTs after 48 h of
administration, but it was no longer observed after 1 month of
exposure.
In general, the results of acute and semiacute exposure
showed that the administration of HNTs or FHNTs by oral or
respiratory routes, as well as their simultaneous administration
by several parenteral routes (up to 20 mg Kg−1 nanoclays), did
not induce any significant physiological change in the mice,
suggesting that they were in good health and positioning
nanoclays as a material with very highly biocompatibility.
These results are in contrast to the previously reported loss of
appetite, decreased body weight, and induction of inflamma-
tory response in mice after the inhalation of HNTs.54 Although
the reason for these differences is unknown, it is likely to be
related to the use of different strains of mice (CD1 vs
Kunming) but above all to the exposure dose, because unlike
our study where mice were exposed to a single dose of HNTs,
the mice in the aforementioned study were exposed to HNTs
for 14 days.54
2.5. HNT and FHNT Accumulation after Acute and
Semiacute Exposure. The simultaneous administration of 5
mg Kg−1 nanoclay by each parenteral route (cutaneous,
subcutaneous, intramuscular, and intraperitoneal; 20 mg Kg−
nanoclay to each mouse) resulted in nanoclay clumps in the
application site, observed 30 days post-exposure (Figure 4A;
Supporting Information S1). The above observation means
that most FHNT and HNT nanoparticles did not spread
throughout the body, supporting their use for some biomedical
applications.
The accumulation of HNTs and FHNTs on the kidney,
liver, and lung of treated mice was evaluated by quantifying
aluminum using atomic absorption spectroscopy. Results
showed nanoclays in the liver, lung, and kidney of orally and
respiratory treated mice but not in the organs of mice
simultaneously administered with all the parenteral routes
(Figure 4B; Supporting Information Figure S1). A higher
accumulation of HNTs than that of FHNTs was observed in
mice at 48 h postexposure (Figure 4A), mainly identified in the
kidney and liver of mice treated orally and lung of mice treated
by inhalation with the 5 mg Kg−1 dose. On the other hand, at
30 days after exposure, less aluminum was detected in the liver,
but the same amount remained in the kidney of orally and
orally plus parenteral treated mice. In mice treated by
inhalation, aluminum was detected in the lungs as expected,
and the amount remained similar at 48 h and 1 month
postexposure (Figure 4B).
In summary, the maximum aluminum accumulation in the
HNTs group was observed in kidneys of orally treated and
lungs of inhalation-treated mice at 48 h post-treatment with
1.5% of the maximum amount of aluminum expected, that is,
0.49 μg (Figure 4B, upper graphs). In contrast, the maximum
accumulation of aluminum in the FHNT group was observed
at 30 days post-treatment with 0.9% (0.294 μg Al) in the
kidney of orally treated and 0.5% (0.163 μg Al) in the lung of
inhalation-treated mice (Figure 4B, lower graphs). These
values are close to the 0.28−0.76% absorption efficiency
reported in subjects ingesting 3 mg Al/day (0.04 mg Al/kg/
day) or 4.6 mg Al/day (0.07 mg Al/kg/day), a dose much
lower than the regular intake of aluminum in food. The
aluminum percentages reported here were calculated consid-
ering the possible maximum amount that each administration
route could reach. These percentages of Al accumulation in
HNT-treated mice can be considered negligible.
The results regarding aluminum accumulation in mice
treated with FHNTs suggest that functionalization with
polystyrene made the nanoclays more rapidly mobilized from
the injection site to the target organs than HNTs, and
therefore, they were excreted faster from the body. The higher
persistence of HNTs than that of FHNTs inside the body
could be due to its lower solubility, a physical feature of less
biocompatible particles.52,53 These results agree with different
Figure 4. Accumulation of halloysite nanoclays in acute and semiacute treated mice. (A) The image shows the subcutaneous accumulation of
FHNTs (arrow) at the injection site after 1 month of administering a single 5 mg Kg−1 dose. (B) Percentage of aluminum determined by atomic
absorption in the kidney, liver, and lung of mice treated with HNTs or FHNTs at 48 h and 1 month after administration. The percentage was
calculated according to the maximum expected amount of aluminum, as described in the experimental section.
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studies dealing with the bioavailability and accumulation of
aluminum after oral and inhalation exposure. These reports
show that the Al concentration increases on target organs such
as the lungs, liver, bone, and spleen after 8 days of a single
gavage of 2.6 mg of Al but rapidly decreases after 3 days of Al
source withdrawal. Absorbed aluminum is primarily excreted in
the urine, with a small amount of absorbed aluminum excreted
in the feces.55 The administration routes assayed in the present
study tried to emulate the general ways of nanoclay exposure
and the toxicological accumulation response. Other admin-
istration routes such as intravenous administrations are highly
recommended for particular uses such as drug delivery and
merit further investigation. Still, acute exposure experiments
described above confirm the biocompatibility of HNTs and
FHNTs for doses up to 25 mg Kg−1.
2.6. Chronic Exposure. To the best of our knowledge, no
study has been reported evaluating the effect in several
generations of animals exposed to FHNTs or HNTs. Chronic
toxicity of nanoclays followed up through three generations (P,
F1, and F2) was explored by exposing mice to HNTs or
FHNTs (3 cm3) into the bed material for 8 months. As the
mice are permanently exposed, it is expected that the nanoclays
will be ingested and aspirated and will adhere to the skin and
hair of the animals throughout the 8 months. Even the eye, ear,
and genital mucosa could be exposed to nanoclays. Even
mating and parturition occurred in the presence of the
nanoclays. Results showed no signs of illness for P or any
member of F1 and F2 generations, including no changes in the
body weight (Supporting Information Figure S2). Progeny
numbers and survival of newborn mice were comparable to the
untreated controls, and no congenital malformations were
observed in three inbred generations.
The histological analysis of the liver, kidneys, lungs, spleen,
heart, and reproductive and gastrointestinal systems after 8
months of permanent exposure to ca. 1 mg of nanoclay showed
the absence of inflammatory processes and tissue damage in all
animals of the three generations treated with HNTs or FHNTs
(Figure 5). Our results agree with those reported by Wang and
co-workers, who observed that a repeated dose of 5 mg Kg−1
body weight for 1 month did not cause liver or lung damage.32
However, higher doses such as 50 mg Kg−1 produce oxidative
damage and fibrotic response in the lungs, suggesting that
HNTs can be toxic when the animals are overexposed to very
high doses.32,33,56 However, they are doses to which a human
could hardly be exposed regularly.
Overall, our results demonstrate that permanent exposure of
mice to halloysite nanoclays does not cause inflammation or
detectable damage in parental or offspring mice and that
polystyrene functionalization does not affect their high degree
of biocompatibility. This innocuousness of nanoclays to
prolonged exposures to low doses could be associated with
their low proinflammatory potential and the rapid mobilization
of the nanoparticles toward organs of excretion such as the
kidney and gastrointestinal tract. In contrast, exposure to
engineered TiO2 nanoparticles and black carbon particles
affects male reproductive function after fetal and adulthood
exposure, including maternal gestational exposure to titanium
dioxide nanoparticles by the subcutaneous injection, intranasal
instillation, or intravenous route.57−61
Figure 5. Photomicrographs showing hematoxylin−eosin staining of the lung, kidney, liver, and subcutaneous tissue of untreated mice (control
group) and those treated with HNTs and FHNTs. No inflammatory infiltration or damaged tissue was observed. The samples were taken of F2
mice exposed to HNTs and FHNTs as the bed material. F2 mice were euthanized after the completion of 8 months of exposure to nanoclays.
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In summary, concentrations of up to 100 μg mL−1 of
FHNTs confirm their high cytocompatibility with human and
murine macrophages. Besides, their high biocompatibility with
CD1 mice after acute, semiacute, chronic, and generational
effects was documented with doses up to 25 mg Kg−1 for the
former and through permanent exposure to ca. 1 mg of
nanoclay for 8 months for the latter. The remarkable cyto-/
biocompatibility of FHNTs could enhance the therapeutical
and diagnostic properties of polystyrene−FHNTs previously
described.
3. CONCLUSIONS
The use of nanomaterials for biomedical applications continues
to be limited by toxicity issues. This work evaluated the cyto-
and biocompatibility of HNTs and FHNTs on in vitro and in
vivo models. Our results show that HNTs and FHNTs did not
substantially affect the viability of human and mice macro-
phages at concentrations as high as 100 μg mL−1. At this
concentration, FHNT induces the release of some proin-
flammatory cytokines in these cells, followed by the
consequent production of anti-inflammatory cytokines, prob-
ably as physiological feedback for controlling inflammation.
The cytokines levels induced by FHNTs were consistently
lower than that of HNTs and, in turn, much quieter than those
caused by talc, considered innocuous.
No adverse effects were determined on mice treated by
different administration routes, and no signs of illness were
observed, neither acute nor chronically exposed mice. We
found low accumulation of the nanoclay in the target organs
kidney, lungs, and liver after 24 h and 30 days of exposure.
Additionally, no modifications on the liver and kidney
functionality serum biomarkers confirms their high biocompat-
ibility with CD1 mice with doses of up to 25 mg Kg−1
administered by several parenteral routes simultaneously.
Furthermore, permanent exposure to ca. 1 mg of nanoclay
for 8 months for parents and pups did not evidence damage on
the three generations studied. Although both nanoclays
exhibited high biocompatibility, FHNTs resulted in a slightly
better disposal, suggesting that this modification can even
improve its safety use in humans. In summary, all results
reported here support the notion of polystyrene−halloysite
nanotubes as a highly biocompatible material, supporting their
use for future biomedical and general-purpose applications.
4. MATERIALS AND METHODS
4.1. Nanoclays and Stock Solutions. Styrene-function-
alized nanoclays (FHNTs) and nonfunctionalized nanoclays
(HNTs) were provided by Centro de Investigacio ́n y
Desarrrollo Tecnoloǵico S.A de C.V, Lerma, Edo. De Mex́ico.
Homogeneous stock suspensions of each nanoclay were
prepared in a phosphate-buffered saline (PBS) solution at 50
mg mL−1 by sonication. For cutaneous applications, nanoclays
were mixed in Vaseline with 1, 2.5, and 5 mg in 500 μL.
4.2. Macrophage Culture and Cytotoxicity Assays.
Cytotoxicity was systematically evaluated on human monocyte-
derived macrophages (HMDM) and mouse bone marrow-
derived macrophages (MMDM). Besides, macrophages from
the RAW 264.7 cell line were used for comparative purposes
(ATCC Cell Biology Collection; Promochem LGC, Molsheim,
France). Macrophages were cultured in an RPMI 1640
medium supplemented with 10% fetal bovine serum (Bio
Whittaker), 500 μg mL−1 gentamicin (Biosera), and 1% 2-
mercaptoethanol (GIBCO, Invitrogen) at 37 °C under a 5%
carbon dioxide humidified atmosphere.
Human monocytes were purified from pooled blood samples
of 10 healthy donors (Hospital Arnau de Vilanova, Lleida,
Spain) by Ficoll-Paque PLUS gradients (GE Healthcare,
Sweden). Monocytes were incubated for 2 h in the
supplemented RPMI 1640 medium at 1 × 105 cells mL−1,
and washings discarded the nonadherent cells with the RPMI
medium. Adherent cells were cultured for 6 days at 37 °C
under 5% CO2 with changes of RPMI culture media every 48
h. HMDM were identified under a microscope and by flow
cytometry.
MMDM were obtained from 4 weeks old CD1 mice. Briefly,
the femur and shinbones were extracted and put in absolute
ethanol for 3 min; after that, they were washed with
supplemented RPMI 1640 culture media. Bone marrow cells
were manually removed from the bones and collected by
centrifugation. Erythrocytes were lysed with water and 10×
PBS; meanwhile, the white cells were washed with PBS and
resuspended in the fresh culture medium. White cells were
cultured in Petri dishes with 10 mL of RPMI 1640 culture
medium, changing the culture medium every 48 h for 5 days to
support the differentiation of monocytes into macrophages.
MMDM were identified under a microscope and by flow
cytometry.
The RAW 264.7 cell line was acquired from the ATCC and
cultured in Petri dishes with the supplemented RPMI 1640
culture medium described above for HMDM.
For each experiment, 1 × 105 macrophages in 100 μL of the
supplemented RPMI 1640 medium were placed in 96-well
plates. FHNTs or HNTs were added at final concentrations of
0.01, 0.1, 1, 10, or 100 μg mL−1 per individual well. Control
cultures were macrophages exposed to 0.01−100 μg mL−1 of
talc, run in parallel with the experimental groups. Cells were
incubated at 37 °C under 5% CO2. Apoptosis/necrosis
induced by FHNTs, HNTs, and talc were determined with
Annexin V and propidium iodide (Annexin V-FITC Apoptosis
Detection kit I, BD Pharmingen) at 12, 24, 36, and 48 h of
exposure by flow cytometry according to the manufacturer’s
protocol. Three independent experiments were performed in
triplicate for each agent assayed.
4.3. Determination of Th1 and Th2 Cytokines.
Production of IFN-γ, IL-1α, IL-6, IL-8, IL-10, and IL-17
cytokines was measured in the supernatants of macrophage cell
cultures exposed to 100 μg mL−1 FHNTs, HNTs, or talc for
24, 36, and 48 h. Quantification of the mentioned cytokines
was performed by flow cytometry using the mouse and human
Th1/Th2 10 plex FlowCytomix kit (eBioscience) according to
the supplier’s instructions.
4.4. Acute and Semiacute Toxicity Assay. Four weeks
old CD1 mice were maintained under sterile conditions with
food and water ad libitum. The use of animals in this project
was authorized by the Internal Committee for the Care and
Use of Laboratory Animals (CICUAL), UNAM, registered
with ID 246. Mice were randomly divided into two groups, one
for acute treatment and the other for semiacute exposure; in
turn, the groups were subdivided for separate FHNT and HNT
treatments. Considering the higher volume suggested for the
parenteral administration of substances to laboratory animals
(0.1 mL)62 and the stock solution concentration (50 mg
mL−1), the maximum dose employed for acute and semiacute
toxicity assays was 5 mg Kg−1.
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For acute treatments, male mice were given a unique dose of
1, 2.5, or 5 mg Kg−1 of FHNTs or HNTs by one of the
following routes: (i) respiratory, using a powder dispersion
chamber where each mouse, one by one, was kept for 5 min
until it breathed in the indicated amount of the nanoclay
(previously, we determined that 5 min within the chamber is
enough time for recovering almost nothing of the nanoclay
powder, suggesting that the mouse breathed it in); (ii) oral,
using a neonatal feeding tube for the direct administration to
the stomach; (iii) parenteral, by injecting a maximal volume of
100 μL of the agent simultaneously by cutaneous, subcuta-
neous, intramuscular, and intraperitoneal routes on each
animal; and (iv) a combined administration scheme, parenteral
routes (as in iii) in addition to oral administration (as in ii) on
each animal. Groups of 15 mice were used for each treatment,
of which three mice (triplicates) were euthanized at 1, 2, 3, 7,
and 30 days after administration using CO2. Additionally, an
untreated five-mice group was used as the control and
euthanized at day 30. Blood samples were collected for
serological analysis. Besides, the application site tissue was
dissected for histopathological examination. Systemic target
organs such as kidneys, livers, and lungs were excised and
processed to determine the tissue accumulation of nanoclays
by aluminum quantification (see below). Mice body temper-
ature and weight were determined every day throughout the
experiment.
4.5. Chronic Exposure through Generations. For
chronic exposure, mice couples were placed in individual
cages and allowed to reproduce for two generations. The
generational effect of permanent exposure to the nanoclays was
evaluated starting with four pairs of 4 weeks old CD1 mice per
nanoclay. Mice were kept in sterile conditions with food and
water ad libitum in cages containing 3 cm3 of FHNTs or HNTs
in the bed material. The bed material was replaced every 72 h
for 8 months. Thus, the parent mice (P) and offspring (F1 and
F2 generations) were constantly exposed to the nanoclays
during feeding, mating, and new litters born. Mice body
temperature and weight were determined once a week
throughout the whole experiment.
Similarly, the number of live pups was recorded, along with
the general condition and behavior of mice. After 8 months of
the initial mating, mice were euthanized with CO2.
Histopathology studies were performed in organs from the
couples of parents and 10 mice of each F1 and F2 generation
(5 female and 5 male mice). Analysis of the stained tissue
sections from the liver, kidney, lung, spleen, heart, and
reproductive and gastrointestinal systems was performed.
Animals without nanoclays in the bed material with the same
experimental scheme were used as the control.
4.6. Nanoclay Accumulation in the Liver, Kidney, and
Lung. The bioaccumulation of nanoclays beyond the injection
site in exposed mice was determined on each target organ such
as the liver, kidney, and lung by quantifying aluminum by
atomic absorption spectroscopy. The maximum expected
aluminum content in mice was estimated considering the
halloysite empirical formula Al2Si2O5(OH)4·4H2O with a
molecular weight of 258 g mol−1. 2 equiv of aluminum in
the minimal formula represent 16.35% in each nanoclay
sample. Aluminum quantification was performed only in the
mice that received the highest amount of each nanoclay
considering the amount of total nanoclay applied to different
experimental groups: respiratory and oral, 5 mg Kg−1;
parenteral, 20 mg Kg−1 (5 mg Kg−1 for each administration
route: cutaneous, subcutaneous, intramuscular, and intra-
peritoneal); and combined oral plus parenteral scheme, 25
mg Kg−1. Considering that the higher dose administered for
mice by oral and respiratory routes is 5 mg Kg−1 in weight and
taking an average mice weight of 40 g, we can expect the
maximum quantity of aluminum in a mouse of these groups to
be around 32.7 μg. In the combined scheme (treatment IV)
case, the maximum expected aluminum quantity is 163.5 μg.
4.7. Liver and Kidney Function Tests. Serological
analyses of blood samples from mice at 24 h and 1 month
postadministration (representing acute and semiacute exposure
to the nanomaterials) were used to evaluate the liver and
kidney function. Biochemical parameters such as aspartate
aminotransferase, alanine aminotransferase, urea, creatinine,
bilirubin, and total proteins were determined using standard
methods of a clinical analysis laboratory for small species.
4.8. Statistical Analysis. Data from viability assays were
analyzed using a two-way ANOVA (p < 0.05) and Tuckey’s
post hoc test (p < 0.05).
4.9. Photomicrography. Images were acquired using the
Nikon MICROPHOT-FXA microscope attached to a Nikon
digital camera (DXM1200F) and a computer with Nikon
ACT-1 software. The objectives used were 20× and 40×.
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